Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 38 clinical trials
Prophylactic Irradiation to the Contralateral Breast for BCAs Patients

germline mutations in genes, such as BRCA1, BRCA2 and PALB2. The cumulative breast cancer risk for BRCA1, BRCA2 or PALB2 mutation carriers was high. Besides the increased breast cancer risk for the

endocrine therapy
trastuzumab
lumpectomy
BRCA2
hormone therapy
  • 0 views
  • 25 Jul, 2021
  • 7 locations
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations (ORCHID)

, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A, RAD51B, RAD51D, or RAD54L who have had prior treatment with at least one immune checkpoint inhibitor or anti-VEGF

RAD54L
BAP1
bevacizumab
ATM
BRIP1
  • 21 views
  • 09 Feb, 2022
  • 1 location
Olaparib In Metastatic Breast Cancer

This research study is for patients with metastatic breast cancer. Metastatic means that the cancer has spread beyond the breast. In addition, through genetic testing of the blood or tumor, an altered gene has been found that suggests the tumor may not be able to repair its genetic material (DNA) …

immunological adjuvant
denosumab
BRCA2
bisphosphonates
aromatase inhibitor
  • 201 views
  • 01 Mar, 2022
  • 19 locations
Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

This phase II trial studies how well olaparib works in treating patients with biliary tract cancer that has spread to other places in the body (metastatic) and with aberrant DNA repair gene mutations. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell …

blood transfusion
cancer
luteinizing hormone (lh)
platelet count
metastatic biliary tract cancer
  • 0 views
  • 29 May, 2022
  • 5 locations
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

This phase I/II trial studies the side effects and best dose of liposomal irinotecan and rucaparib when given together with fluorouracil and leucovorin calcium and to see how well they work in treating patients with pancreatic, colorectal, gastroesophageal, or biliary cancer that has spread to other places in the body …

homologous recombination deficiency
parp inhibitor
irinotecan
metastatic adenocarcinoma
metastasis
  • 8 views
  • 16 Jun, 2022
  • 3 locations
Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer With DNA-Repair Genetic Changes

This phase II trial studies how well olaparib works in treating patients with urothelial cancer with deoxyribonucleic acid (DNA)-repair defects that has spread to other places in the body (advanced or metastatic) and usually cannot be cured or controlled with treatment. PARPs are proteins that help repair DNA mutations. PARP …

cancer
nivolumab
neutrophil count
atezolizumab
avelumab
  • 111 views
  • 20 Jun, 2022
  • 1 location
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

The aim of this single-arm phase 2 clinical trial is to evaluate the anti-cancer activity of Talazoparib (also known as BMN 673) in patients with advanced breast cancer with specific genetic or tumor genomic alterations. Patients with either triple-negative or HER2-negative breast cancer are eligible.

brca2 mutation
solid tumor
her2/neu-negative breast cancer
triple-negative breast cancer
advanced breast cancer
  • 5 views
  • 08 Sep, 2021
  • 1 location
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

Olaparib has demonstrated preliminary efficacy in metastatic castration-resistant prostate cancer. In a trial of 49 evaluable patients treated with olaparib, 11 / 49 experienced a PSA response, and every patient with a radiographic response also had a PSA5 response. Ten of 11 responders had mutations in DNA repair genes. While …

prostatectomy
cancer
metastatic disease
platelet count
androgens
  • 8 views
  • 23 Mar, 2022
  • 4 locations
The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency

The purpose of this trial is to compare the 3-year disease-free survival of dose-dense epirubicin and cyclophosphamide followed by paclitaxel with paclitaxel plus carboplatin as adjuvant therapy for triple-negative breast cancer with homologous recombination repair deficiency. The other purpose of this trial is to observe the patient's tolerance.

  • 0 views
  • 22 Jan, 2021
  • 1 location
Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH)

The aim of this research is to find out if the study drug rucaparib leads to lowering of PSA levels in men with metastatic prostate cancer that has not yet been treated with androgen deprivation therapy (also referred to as metastatic hormone sensitive prostate cancer) and who have an inherited …

serum testosterone
testosterone level
androgen ablation
platelet count
antiandrogen therapy
  • 162 views
  • 29 Apr, 2022
  • 2 locations